

Nicholas Turner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1886466/publications.pdf>

Version: 2024-02-01

23
papers

2,543
citations

933447

10
h-index

1125743

13
g-index

23
all docs

23
docs citations

23
times ranked

5558
citing authors

#	ARTICLE	IF	CITATIONS
1	Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 565-576.	2.5	32
2	Abstract P5-16-11: Ipatasertib (ipato) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC). <i>Cancer Research</i> , 2022, 82, P5-16-11-P5-16-11.	0.9	1
3	Abstract P1-18-35: Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level <i>FGFR1</i> amplification: Preliminary data from a phase 2 study. <i>Cancer Research</i> , 2022, 82, P1-18-35-P1-18-35.	0.9	1
4	Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1321-1337.	13.2	66
5	Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. <i>Nature Cancer</i> , 2021, 2, 1305-1320.	13.2	123
6	Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 101-111.	2.5	17
7	Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk. <i>European Radiology</i> , 2020, 30, 6702-6708.	4.5	14
8	Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100188.	1.7	13
9	Abstract GS2-07: Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). , 2020, , ,		13
10	Abstract GS3-06: Results from the plasmaMATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010). , 2020, , ,		8
11	Abstract GS3-07: The genomic landscape of breast cancer based on ctDNA analysis: Data from the plasmaMATCH trial. , 2020, , ,		1
12	Abstract P1-19-07: Results from plasmaMATCH trial treatment cohort B: A phase II trial of neratinib plus fulvestrant in ER positive breast cancer or neratinib alone in ER negative breast cancer in patients with aHER2mutation identified via ctDNA screening (CRUK/15/010). , 2020, , ,		1
13	Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , 2020, 80, PD5-03-PD5-03.	0.9	34
14	Abstract P1-19-11: Results from plasmaMATCH trial treatment cohort C: A phase II trial of capivasertib plus fulvestrant in ER positive breast cancer patients with anAKT1mutation identified via ctDNA screening (CRUK/15/010). , 2020, , ,		0
15	Abstract P1-19-04: Results from plasmaMATCH trial treatment cohort A: A phase II trial of extended-dose fulvestrant in patients with an ESR1 mutation identified via ctDNA screening (CRUK/15/010). , 2020, , ,		0
16	Abstract P1-19-14: Results from plasmaMATCH trial treatment cohort D: A phase II trial of capivasertib in patients with an AKT activation basket mutation identified via ctDNA testing or tumour sequencing (CRUK/15/010). , 2020, , ,		0
17	Abstract P1-19-29: An integrated safety analysis of talazoparib monotherapy from five clinical trials (phase 1-3) in advanced cancers. , 2020, , ,		0
18	Reply to J.A. Sparano et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 1842-1842.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Endocrine-based therapy versus chemotherapy in advanced breast cancer. <i>Lancet Oncology</i> , The, 2019, 20, 1632-1633.	10.7	4
20	Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk. <i>Journal of Clinical Oncology</i> , 2019, 37, 689-692.	1.6	26
21	Predicting Relapse with Circulating Tumor DNA Analysis in Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 1368-1370.	9.4	17
22	Abstract 2408: A novel multiplex droplet digital PCR approach to KRAS mutation detection in circulating tumor DNA., 2015,, .		0
23	Fibroblast growth factor signalling: from development to cancer. <i>Nature Reviews Cancer</i> , 2010, 10, 116-129.	28.4	2,172